FDA Opens Door for Moms in Medicine Testing
Published Date: 7/21/2025
Notice
Summary
The FDA just dropped new draft guidance to help include pregnant and breastfeeding women in medicine testing. This means drug makers will get clearer rules on how to safely study medicines for moms-to-be and nursing moms, so everyone gets better info on what’s safe and effective. This change could speed up research and improve health for millions, with no big cost surprises yet.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Guidance to Include Pregnant Participants
The FDA released draft guidance that tells drug companies general principles for running clinical trials that include pregnant women. You, as a pregnant person, could get better information about medicine safety and use because trials would explicitly include people like you.
Data on Safety, Dosing, Efficacy
The draft guidance describes approaches to generate data on safety, dosing, and how well medicines work during pregnancy and breastfeeding. If you are pregnant or breastfeeding, those approaches are intended to give doctors clearer, evidence-based information about which doses and medicines are safe and effective for you.
Recruitment and Participant Burden Guidance
The guidance includes recommendations for recruiting and keeping pregnant and breastfeeding women in clinical trials while reducing burden and harm to those participants. This means trial designs may change to make it easier and safer for pregnant and nursing people to take part.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-13676 — Agency Information Collection Activities: Proposed Collection; Comment Request
CMS wants your thoughts on their plan to collect info from the public and is asking for comments over the next 60 days. This helps make sure the questions they ask aren’t too much work and actually useful. If you’re someone who deals with CMS forms, this is your chance to speak up before any changes happen.
Next: 2025-13681 — Morgan Stanley Pathway Funds and Consulting Group Advisory Services LLC
Morgan Stanley Pathway Funds and Consulting Group Advisory Services want permission to change their subadvisory agreements without asking shareholders every time. They’re also asking to share less info about fees paid to subadvisers. If approved, this could speed up how they manage funds, with a decision expected by mid-August 2025.